First Clinical Study with AP30663 ‐ a K Ca 2 Channel Inhibitor in Development for Conversion of Atrial Fibrillation-Reference-Cited by-同舟云学术

First Clinical Study with AP30663 ‐ a K Ca 2 Channel Inhibitor in Development for Conversion of Atrial Fibrillation

Published:2020-07-29 Issue:6 Volume:13 Page:1336-1344
ISSN:1752-8054
Container-title:Clinical and Translational Science
language:en
Short-container-title:Clin Transl Sci

Author:

Gal Pim¹²,Klaassen Erica S.¹,Bergmann Kirsten R.¹,Saghari Mahdi¹,Burggraaf Jacobus¹²³,Kemme Michiel J. B.⁴,Sylvest Christina⁵,Sørensen Ulrik⁵,Bentzen Bo H.⁵,Grunnet Morten⁵,Diness Jonas G.⁵,Edvardsson Nils⁵⁶

Affiliation:

1. Centre for Human Drug Research Leiden The Netherlands

2. Leiden University Medical Centre Leiden The Netherlands

3. Leiden Academic Center for Drug Research Leiden The Netherlands

4. Department of Cardiology Amsterdam UMC Amsterdam The Netherlands

5. Acesion Pharma ApS Copenhagen Denmark

6. Department of Molecular and Clinical Medicine/Cardiology Institute of Medicine Sahlgrenska Academy University of Gothenburg Gothenburg Sweden

Publisher

Wiley

Subject

General Pharmacology, Toxicology and Pharmaceutics,General Biochemistry, Genetics and Molecular Biology,General Medicine,General Neuroscience

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/cts.12835

Reference21 articles.

1. Safety and efficacy of pharmacological cardioversion of recent-onset atrial fibrillation: a single-center experience

2. Survival with oral d-Sotalol in patients with left ventricular dysfunction after myocardial infarction: Rationale, design, and methods (the SWORD trial)

3. Events in the cardiac arrhythmia suppression trial (CAST): Mortality in the entire population enrolled

4. Inhibition of Small-Conductance Ca 2+ -Activated K + Channels Terminates and Protects Against Atrial Fibrillation

5. Effects on Atrial Fibrillation in Aged Hypertensive Rats by Ca 2+ -Activated K + Channel Inhibition

Cited by 22 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Genetics and Pharmacogenetics of Atrial Fibrillation;JACC: Basic to Translational Science;2024-07

2. Weekly journal scan: the KCa2 potassium channel as a promising target for the pharmacologic cardioversion of atrial fibrillation;European Heart Journal;2024-04-01

3. Pathophysiology and clinical relevance of atrial myopathy;Basic Research in Cardiology;2024-03-12

4. A phase 1 trial of AP30663, a K_Ca2 channel inhibitor in development for conversion of atrial fibrillation;British Journal of Clinical Pharmacology;2024-01-08

5. Inhibition of the KCa2 potassium channel in atrial fibrillation: a randomized phase 2 trial;Nature Medicine;2023-12-13